News
KYSAM and ASAM Urge Review Committee to Reject Deficient Buprenorphine Regulation
On October 13, the Kentucky Society of Addiction Medicine (KYSAM) along with the American Society of Addiction Medicine (ASAM) submitted a joint statement to the Kentucky General Assembly Administrative Regulation Review Subcommittee ahead of its October hearing. The statement urged committee members to find the proposed 201 KAR 9:270 deficient and recommended that the Kentucky Board of Medical Licensure (KBML) amend the proposal to correct the deficiencies.
The joint statement highlighted specific examples of deficiencies in the proposed 201 KAR 9:270 regulation, including deficiencies relating to prior medical records, behavioral modification services, and the incorporation of the Substance Abuse and Mental Health Services Administration (SAMHSA)’s Treatment Improvement Protocol (TIP) 63. At a minimum, the joint statement called for these deficiencies to be sufficiently addressed before any approval of the KBML proposal. This joint statement is the latest chapter in KYSAM’s ongoing effort to push back against this deficient proposal and to improve access to evidence-based treatment for people with opioid use disorder in Kentucky.
Ultimately, the committee decided to defer the proposal for another month to allow for more consideration.